Search
Filter Results
Displaying 261–270 of 829 for “retinal diseases”
-
Mar 21, 2012
The Importance of Stem Cells (a guest post from Dr. David Gamm)
Dr. David Gamm on the potential of stem cell research to benefit patients with retinal degenerations.
-
Feb 14, 2013
How an FDA-Approved Retinal Prosthesis Came To Be
The Argus II Retinal Prosthesis System was recently granted market approval by the U.S. Food and Drug Administration (FDA), which marks a significant milestone in the development of a therapy that has spanned more than 20 years.
-
Jun 18, 2020
Bionic Sight Doses First Patient in Clinical Trial for Optogenetic Therapy
Treatment combines gene therapy and a device that generates and delivers retinal code
-
Mar 24, 2021
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
The company is planning two Phase 2/3 clinical trials for the treatment
-
Dec 10, 2020
Mr. Ginsberg brings twenty-five years of rare disease corporate development, finance, strategy, and investment leadership experience.
-
Jul 29, 2020
Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness
-
Career Development Program (CDA)
Objective/Goal: The goal of this Program is to facilitate advances in laboratory and clinical research, to elucidate the mechanisms for the etiology and pathogenesis of retinal degenerative diseases and to develop innovative strategies to prevent, treat and cure these diseases. This program supports up to five junior-level faculty for five (5) years. $75,000/year
-
Feb 28, 2023
RD Fund Appoints Mark S. Blumenkranz, MD, MMS to Board of Directors
Ophthalmology visionary Mark S. Blumenkranz, MD, MMS, to join RD Fund’s Board.
-
Nov 29, 2023
Foundation Fighting Blindness Appoints Jeff Klaas as Chief Strategy and Innovation Officer
Klaas brings over twenty years of experience to lead strategies aimed at elevating engagement and revenue.